X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells to treat cartilage injury, including osteoarthritis of the knee.
Lead Product(s): Mesenchymal Stem Cell Therapy
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sengkang General Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 04, 2024
Details:
This collaboration aims to develop new treatment modalities by using gamma-delta T cells (gdTc) for the treatment of acute myeloid leukemia (AML) and breast cancer patients at an affordable cost.
Lead Product(s): Gamma Delta T Cell-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 09, 2023
Details:
The net proceeds from the initial public offering will be used to advance the clinical development of the Company's CTM-N2D product candidate and to continue technology development of the Company's iPSC-gdNKT product candidate.
Lead Product(s): CTM-N2D
Therapeutic Area: Oncology Product Name: CTM-N2D
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Benchmark Company
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
